Inmed provides update on inm-089 in the treatment of dry age-related macular degeneration

Small molecule drug acting as a preferential signaling ligand for cb1/cb2 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model vancouver, british columbia--(newsfile corp. - april 16, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data for inm-089 further demonstrating positive pharmacological effects targeting dry age-related macular degeneration ("amd"). dr. eric hsu, svp of preclinical research and development, stated, "we are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from inm-089 in the amd model.
INM Ratings Summary
INM Quant Ranking